Research programme: interferon beta - HanAll Biopharma
Alternative Names: HL144; Interferon-beta - HanAll BiopharmaLatest Information Update: 11 Mar 2011
At a glance
- Originator Nautilus Biotech
- Developer HanAll Biopharma
- Class Interferons
- Mechanism of Action Interferon beta stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes
Highest Development Phases
- No development reported Multiple sclerosis
Most Recent Events
- 11 Mar 2011 No development reported - Preclinical for Multiple sclerosis in South Korea (SC)
- 21 Sep 2010 Research programme: interferon beta - HanAll Pharmaceutical is available for licensing (www.hanallbiopharma.com)
- 20 Jul 2004 This programme is available for licensing (http://www.nautilusbiotech.com)